Latest News
-
Wednesday - December 20, 2017
Not intended for U.S. and UK Media
Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers
Completion of NDA submission expected in early 2018 » more
-
Wednesday - December 13, 2017
Not intended for U.S. and UK Media
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic treatment of liver cancer
Approval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib) » more
-
Monday - December 11, 2017
Not intended for U.S. and UK Media
Bayer’s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack / The application for marketing approval is based on the COMPASS study » more
-
Thursday - December 7, 2017
Not intended for U.S. and UK Media - American Society of Hematology (ASH) 59th Annual Meeting & Exposition:
Thirteen abstracts highlighting data from Bayer’s rivaroxaban will be presented at ASH 2017, two addressing cancer-associated thrombosis
Results from Select-D trial demonstrate lower rates of venous thromboembolism (VTE) recurrence with rivaroxaban than with the current standard of care / The development of VTE in cancer patients is associated with high morbidity and mortality / Rivaroxaban abstracts covering both clinical and real-world studies in venous and arterial thromboembolism » more
-
Thursday - December 7, 2017
Bayer is taking a leadership role in driving transparency:
New Bayer transparency website launched
Enabling access to safety-relevant plant protection study summaries / Fostering an open and transparent dialog with society / Support to authorities in dealing with data requests » more
-
Thursday - December 7, 2017
Not intended for U.S. and UK Media
Bayer to highlight new oncology research at ASH 2017
New data include further safety and efficacy follow-up from the CHRONOS-1 study in indolent non-Hodgkin’s lymphoma » more
-
Thursday - December 7, 2017
Keep your family healthy by protecting your pet from parasites
Many disease-causing pathogens that are transferable from pets to humans are spread by common parasites, such as fleas and ticks / Effective parasite protection for pets is more important than ever before as parasites are spreading beyond their ‘typical’ regions or climates, making zoonotic and vector borne diseases a growing global threat » more
-
Monday - December 4, 2017
Not intended for U.S. and UK Media - American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer Research:
Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers
93 percent overall response rate in 17 pediatric patients with TRK fusion cancers / 94 percent of all patients remain on larotrectinib or received surgery with curative intent, four patients have been followed greater than one year and 12 have been followed greater than six months / Larotrectinib demonstrates central nervous system activity in first-ever TRK fusion glioblastoma response with a TRK inhibitor » more
-
Friday - December 1, 2017
CFIUS completes review of proposed merger of Bayer and Monsanto » more
-
Friday - December 1, 2017
Not intended for U.S. and UK Media - Pharmaceuticals Media Day 2017:
Bayer invests in differentiated drug pipeline with over 50 projects focused on high unmet medical needs
Strengthening oncology presence, a key pillar for future growth, with new product launches, pipeline progress, and a new partnership with Loxo Oncology / Leading in fight against cardiovascular diseases, while aiming for further rivaroxaban indication expansion and novel FXI inhibition programs / Growing portfolio for cardiovascular conditions like heart failure, kidney diseases, and indications adjacent to classical field of cardiovascular diseases in clinical development / Progress in gynecology with six assets in clinical development for uterine fibroids and endometriosis » more
-
Thursday - November 30, 2017
Not intended for U.S. and UK Media
Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early
Decision follows a recommendation from an Independent Data Monitoring Committee » more
-
Thursday - November 30, 2017
Not intended for U.S. and UK Media
Bayer combines pharmaceutical research and development unit » more
-
Tuesday - November 28, 2017
Winners selected for the Aspirin Social Innovation Award 2017:
Bayer Cares Foundation honors social impact pioneers with novel solutions for humanity’s big challenges
Bayer prize is awarded to innovative concepts in the areas of health and nutrition that have the potential to bring about sustainable, systemic change to the world / Since 2010, EUR 255,000 in funding has been granted to 34 initiatives for new approaches aimed at improving living conditions all around the globe » more
-
Monday - November 27, 2017
Bayer ForwardFarming expands to Latin America
New farms in Argentina and Brazil join the global network / Demonstrating how unique regional challenges in sustainable agriculture can be effectively addressed / Growth to continue in the region in 2018 » more
-
Monday - November 27, 2017
E-health and digital farming: Actively shaping the potential of digitalization
Bayer is expanding its collaboration with Bitkom » more
-
Friday - November 24, 2017
Not intended for U.S. and UK Media
Phase III study program with Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority » more
-
Thursday - November 23, 2017
Bayer eases dairy herd health management with "BCS Cowdition" application update
Bayer’s BCS Cowdition smartphone application simplifies and standardizes body condition scoring (BCS) to help farmers and vets identify, tackle and prevent metabolic and fertility problems in dairy cows / Innovative updates to BCS Cowdition enables tailored individual cow assessments, and offers a comprehensive herd dashboard, and further insights garnered from "big data" » more
-
Thursday - November 16, 2017
Not intended for U.S. and UK Media
Bayer and PeptiDream to identify new active substance candidates through novel peptide-based screening technology » more
-
Wednesday - November 15, 2017
Heiko Schipper to join Bayer Board of Management and head Consumer Health Division
Erica Mann to leave Bayer effective March 31, 2018 » more
-
Tuesday - November 14, 2017
Not intended for U.S. and UK Media
Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Larotrectinib (LOXO-101) and LOXO-195 target tropomyosin receptor kinase (TRK) fusion proteins, which are a product of genetic alterations that occur across a range of different tumors / Co-Promotion of the products in the U.S. / Bayer solely responsible for the commercialization of both products outside the U.S. / U.S. filing of larotrectinib planned for late 2017 or early 2018 » more
Copyright @ Bayer AG